Long-Acting Erythropoietin Stimulating Agents for Persistent Anemia After Kidney Transplant: Risk Factors and Outcome
|
|
- Aubrey Ford
- 6 years ago
- Views:
Transcription
1 ARTICLe Long-Acting Erythropoietin Stimulating Agents for Persistent Anemia After Kidney Transplant: Risk Factors and Outcome Torki Al-Otaibi, 1 Osama Gheith, 2 Medhat A. Halim, 1 Hasanein Abu Attia, 1 Hani Mansour, 1 Tarek Said, 1 Prasad Nair, 1 Mohamed Balaha, 1 M. R. Narayanan Nampoory 1 Abstract Objectives: Posttransplant anemia is associated with an increased risk of congestive heart failure, left ventricular hypertrophy, and death. The purpose of this study was to evaluate the effect of long-acting erythropoietin-stimulating agents on anemia after kidney transplant. Materials and Methods: In 2306 kidney transplant recipients, 250 anemic patients (11%) with stable graft function were followed at the Hamed Al-Essa Organ Transplant Centre (Kuwait) and were assessed for anemia. We enrolled 120 patients into this open-label study in 2 groups: group 1 had treatment with darbepoetin alfa (86 patients) and group 2 had continuous erythropoietin receptor activator (34 patients). Results: Patient age correlated negatively with serum iron level. Serum ferritin correlated negatively with hemoglobin level 6 months after transplant but not at time of transplant. Most patients were women who received their grafts from male donors. The 2 groups were comparable in frequency of rejection and mean hemoglobin and serum albumin levels at 3, 6, 9, and 12 months after transplant. There was no difference between the 2 groups in renal function (estimated glomerular filtration rate); posttransplant complications such as new-onset From the 1 Hamed Al-Essa Organ Transplant Center, Ibn-Sinah Hospital, Sabah Area, Ministry of Health, Kuwait; the 2 Mansoura Urology and Nephrology Center, Mansoura University, Mansoura City, Egypt; and the Hamed Al-Essa Organ Transplant Center of, Kuwait Acknowledgements: The author declares that he has no conflicting interests and has received no financial support for this study. Corresponding author: Osama Ahsry Ahmed Gheith, Mansoura Urology and Nephrology Center, Mansoura University, Elgomhouria St., Mansoura City, 35516, Egypt; and Hamed Al- Essa Organ Transplant Center of, Kuwait Phone: Fax: ogheith@yahoo.com Experimental and Clinical Transplantation (2014) 3: diabetes after transplant, hypertension, serious bacterial infections, or patient and graft outcomes. Conclusions: Anemia is an important problem after kidney transplant, and iron use is suboptimal in kidney transplant recipients. Darbepoetin alfa and continuous erythropoietin receptor activator had comparable positive results. Key words: Continuous erythropoietin receptor activator, Darbepoetin alfa, End-stage kidney disease, Hemoglobin, Iron Introduction Anemia is an important risk factor for cardiovascular death in patients who have chronic kidney disease (CKD). 1 Posttransplant anemia has a prevalence from 20% to 60% 2-4 and is associated with an increased risk of congestive heart failure and left ventricular hypertrophy. 2-7 The persistence of posttransplant anemia may be an important contributor to death The pathogenesis of posttransplant anemia is multifactorial, and late posttransplant anemia is associated with renal dysfunction, immunosuppressive drugs, antiviral agents, and the use of angiotensin-converting enzyme inhibitors Severe anemia that requires treatment, based on current guidelines, is less frequent (prevalence, 10%-15%). 15,16 There is controversy about the association between anemia and outcome in kidney transplant recipients Anemia may predict the decline of renal function in CKD patients, but adequate treatment of anemia may slow the decline of renal function. 7,22-24 A retrospective study showed that prevalence of posttransplant anemia is high, especially in women and patients who receive calcineurin inhibitors and mycophenolate mofetil, and posttransplant anemia Copyright Başkent University 2014 Printed in Turkey. All Rights Reserved. DOI: /ect
2 Torki Al-Otaibi et al /Experimental and Clinical Transplantation (2014) 3: was associated with poorer graft outcome but had no effect on patient transplant survival. 25 However, anemia has received less attention in transplant than nontransplant CKD patients because response to erythropoietic therapy may be similar in transplant and nontransplant CKD patients. Conversely, posttransplant anemia can be affected by factors that are unique to transplant recipients. 26 Continuous erythropoietin receptor activator (CERA) is a third generation erythropoiesis-stimulating agent licensed for treatment of symptomatic anemia associated with CKD. The pharmacologic profile and prolonged administration half-life of CERA enable extended administration intervals up to once per month. Several studies have confirmed the efficacy of CERA for anemia correction and maintenance of stable hemoglobin levels in CKD patients However, the information available in kidney transplant recipients is limited. A literature search showed only 1 clinical trial that reported data in this setting; CERA given once per month enabled the maintenance of hemoglobin levels in kidney transplant recipients who had anemia associated with CKD and who changed treatment from darbepoetin alfa. 36 The purpose of this study was to assess different causes of anemia in kidney transplant recipients who had stable graft function and to evaluate anemia control prospectively in kidney transplant recipients who received long acting erythropoietin-stimulating agents. Materials and Methods Patients In 2306 kidney transplant recipients (year 1976 to present), 250 anemic patients had stable graft function, were followed at the Hamed Al-Essa Organ Transplant Centre (Kuwait), and were assessed for the cause of anemia. Anemia was defined according to the Revised European Best Practice guidelines for anemia in kidney transplant (hemoglobin < 110 g/l [11 g/dl]) as the threshold for treatment with erythropoietin-stimulating agents. In the present study, anemia was defined by a hemoglobin level of 120 g/l (12 g/dl) in women and 130 g/l (13 g/dl) in men, and severe anemia was defined by 110 g/l (11 g/dl) in women or men. Patients were included in this open-label study when they (1) were adult kidney transplant patients (age 18 y) who were 6 months after transplant, (2) gave informed consent, (3) had stable maintenance subcutaneous darbepoetin alfa therapy with constant dose during the previous 2 months, and (4) had hemoglobin level 120 g/l (12 g/dl) (hematocrit 0.34 [34%]). Patients were excluded from the study because of (1) acute bleeding or erythrocyte transfusion within the previous 8 weeks, (2) acute hemolytic anemia, (3) recent infection or rejection, (4) acute systemic inflammatory disease and/or high C-reactive protein level > 286 nmol/l (30 mg/l), (5) hemodialysis because of failure of a kidney transplant, (6) creatinine concentration > 300 μmol/l, or (7) malignancy. After correction of iron deficiency and exclusions, 120 patients were enrolled in the study and categorized into 2 groups according to the erythropoietin-stimulating agent used, either darbepoetin alfa (86 patients) or CERA (34 patients). The study adhered to the World Medical Association Declaration of Helsinki (original and all amendments) and national regulations, and was approved by the ethics committee of the transplant center. All patients gave written informed consent. evaluation Each patient was evaluated clinically with history and physical examination monthly in the outpatient clinic. Laboratory tests included complete blood count, hemoglobin electrophoresis, prothrombin time, erythrocyte sedimentation rate, and serum levels of iron, ferritin, transferrin saturation, vitamin B12, folic acid, parathyroid hormone, C-reactive protein, creatinine, creatinine clearance, liver function tests, calcium, phosphorus, and fasting blood sugar. Patients also were tested with urinary protein level (g/24 h), serum drug levels, virology profile (cytomegalovirus, Epstein-Barr virus, and parvovirus), and abdominal ultrasonography. Follow-up evaluation included clinical examination and laboratory tests including complete blood cell count and levels of urea, creatinine, fasting blood glucose, plasma albumin, proteinuria, and drugs. Statistical analyses Data were analyzed with statistical software (SPSS for Windows, version 17.0, SPSS Inc, Chicago, IL, USA). Continuous variables were reported as mean ± standard deviation, and qualitative variables were reported as frequency (number [%]) (sex, ethnicity, hemoglobin values within target ranges,
3 222 Torki Al-Otaibi et al /Experimental and Clinical Transplantation (2014) 3: Exp Clin Transplant and occurrence of adverse events). Univariate and multivariate analyses were used to evaluate correlations between anemia, sex, renal allograft function, diabetes mellitus, and cytomegalovirus infection at 6 months after transplant. Statistical significance was defined by P.05. Results In 2306 kidney transplant patients, 250 patients (11%) were anemic and agreed to participate in the study. All patients were > 6 months posttransplant and were maintained on erythropoietin-stimulating agents. During the preparation phase of the study, we noted that 36 patients (14%) achieved target hemoglobin level > 120 g/l (12 g/dl) by correction of iron deficiency anemia. Serum iron was significantly lower in patients who had anemia (anemia, 11 ± 5; no anemia, 15 ± 6; P.01). Patient age correlated negatively with serum iron (r, ; P.05). Serum ferritin level correlated negatively with hemoglobin level at 6 months after transplant (r, ; P.004) but not at time of transplant (r, 0.08; not significant). Patients in both groups were similar in mean serum C-reactive protein, folic acid, and vitamin B12 level, and most patients had low vitamin D level but no proteinuria. Most patients who were maintained on darbepoetin alfa or CERA were women, and both groups were similar in mean age and received their grafts mostly from men (Table 1). The 2 groups had similar frequencies of comorbidities and transplant characteristics (Table 1). Patients in the CERA group received a mean starting dose of CERA 116 ± 86 μg per month which was significantly lower than that the corresponding equivalent darbepoetin alfa dose (154 ± 73 μg/mo) received by patients of the darbepoetin alfa group during the first 3 months (difference not significant). There was no significant difference between the 2 groups in the mean dosage received during the subsequent 9 months. The mean number of blood transfusions was similar between the 2 groups during the entire study (CERA group, 0.1 ± 0.3 transfusion units/patient; darbepoetin alfa group, 0.2 ± 0.5 transfusion units/patient; not significant). The 2 groups were comparable in frequency of rejection and types of acute rejection episodes (Table 2). The 2 groups had similar mean hemoglobin level and renal function (estimated glomerular filtration rate) at 3, 6, 9, and 12 months after transplant (Table 3). Table 1. Characteristics of Donors and Recipients of Kidney Transplant* (n=86) Receptor Donor age (y) 34 ± ± 10 NS Donor sex (male/female) 66 (77) / 20 (23) 25 (74) / 9 (26) NS Recipient age (y) 42 ± ± 17 NS Recipient sex (male/female) 33 (38) / 53 (62) 14 (41) / 20 NS Original kidney disease Immunologic 25 7 Nonimmunologic NS Pretransplant comorbidities Hypertension NS Diabetes mellitus 22 8 NS Ischemic heart disease 14 6 NS Donor type Living-related Living-unrelated Deceased 26 7 NS Pretransplant dialysis Hemodialysis Peritoneal dialysis 7 4 None 15 9 NS Human leukocyte antigen Type I match Type II match NS Induction immunosuppression Thymoglobulin/Basiliximab None 12 7 NS Maintenance immunosuppression Steroids/MMF/cyclosporine Steroids/MMF/tacrolimus 24 8 Steroids/azathioprine/ cyclosporine 16 5 NS Erythropoiesis-stimulating agent, dose (μg/mo) 3 mo 154 ± ± mo 174 ± ± 73 NS 9 mo 145 ± ± 97 NS 12 mo 158 ± ± 83 NS Abbreviations: MMF, mycophenolate mofetil *N = 120 patients. Data reported as number, mean ± SD, or number (%). Table 2. Rejection Episodes in Kidney Transplant Recipients Who Received Darbepoetin Alfa or Continuous Erythropoietin Receptor * (n=86) Receptor No. of patients who had no rejection 80 (93) 32 (94) NS Total rejection episodes 6 (7) 2 (6) NS Mean No. of rejection episodes 0.57 ± ± 0.6 NS Type of rejection Chronic allograft nephropathy 3 0 Acute cellular rejection 1 1 Mixed (ACR/AMR) 1 0 Antibody-mediated rejection 1 1 NS Abbreviations: ACR, acute cellular rejection; AMR, antibody-mediated rejection *N = 120 patients. Data reported as number (%), mean ± SD, or number.
4 Torki Al-Otaibi et al /Experimental and Clinical Transplantation (2014) 3: The 2 groups had similar frequency of posttransplant complications including level of hypertension (number of antihypertensive drugs) and frequency of new-onset diabetes after transplant and infections (Table 4). Both groups had comparable frequency of cardiovascular complications (acute myocardial infarction, coronary stenting, and arrhythmias) (data not shown). No parvovirus infection was observed in any recipient. There was no significant difference in patient or graft outcome between the 2 groups at the end of the study (mean follow-up, 2.4 y) (Table 5 and Figures 1 and 2). Table 3. Posttransplant Hemoglobin and Renal Function in Kidney Transplant Recipients Who Received Darbepoetin Alfa or Continuous Erythropoietin Receptor * (n=86) Receptor Hemoglobin (g/l): Baseline (2 weeks after transplant) 111 ± ± 12 NS 3 mo 116 ± ± 14 NS 6 mo 112 ± ± 22 NS 9 mo 119 ± ± 15 NS 12 mo 114 ± ± 16 NS Glomerular filtration rate (ml/min) Baseline (2 weeks after transplant) 45.5 ± ± 25 NS 3 mo 44.8 ± ± 25 NS 6 mo 44.6 ± ± 21 NS 9 mo 46 ± ± 31 NS 12 mo 46 ± ± 24 NS *N = 120 patients. Data reported as mean ± SD. Table 4. Posttransplant Complications in Kidney Transplant Recipients Who Received Darbepoetin Alfa or Continuous Erythropoietin Receptor * (n=86) Receptor No. of antihypertensive drugs Before transplant 2 ± ± 0.9 NS After transplant 1 mo 2 ± 1 2 ± 1 NS 3 mo 2 ± 1 2 ± 1 NS 6 mo 2 ± 1 2 ± 1 NS 9 mo 2 ± 1 2 ± 1 NS 12 mo 2 ± 1 2 ± 1 NS New-onset diabetes after transplant 11 (13) 3 (9) NS Bacterial infection 38 (44) 15 (44) NS Urinary tract 14 (16) 10 (29) NS Chest 9 (12) 6 (11) NS Gastrointestinal tract 9 (11) 5 (15) NS *N = 120 patients. Data reported as mean ± SD or number (%). Table 5. Outcomes in Kidney Transplant Recipients Who Received Darbepoetin Alfa or Continuous Erythropoietin Receptor * Outcome Darbepoetin Alfa Continuous Erythropoietin P (n=86) Receptor Patient outcome Alive 84 (98) 32 (94) Dead 2 (2) 2 (6) NS Graft outcome Functioning 83 (96.5) 33 (97) Failed 3 (3.4) 1 (3) NS *N = 120 patients. Data reported as number (%). Figure 1. Continuous Erythropoietin Receptor (CERA) Graft Survival Figure 2. Graft Survival in Kidney Transplant Recipients Who Received Darbepoetin Alfa or Continuous Erythropoietin Receptor (CERA) Patient Survival Discussion P =.40 Time in Years P =.55 Time in Years Final groups Aranesp/CERA Aranesp CERA Final groups Aranesp/CERA Aranesp CERA Ara-Censored CERA-Censored Anemia is more prevalent in allograft recipients than other patients who have CKD matched for glomerular filtration rate. There are limited data available about the correction of anemia with
5 224 Torki Al-Otaibi et al /Experimental and Clinical Transplantation (2014) 3: Exp Clin Transplant erythropoietin-stimulating agents after transplant. The higher degree of anemia in kidney allograft recipients may be attributed to the use of immunosuppressive drugs. Higher doses of erythropoietinstimulating agents are indicated to treat anemia in kidney transplant recipients. 37 The drug CERA was administered to the present patients once per month, and this may simplify treatment for outpatients who self-administer erythropoiesisstimulating agents. 38 In this study, we aimed to assess different causes of anemia in kidney transplant recipients who had stable graft function and to evaluate anemia control prospectively in recipients who received long-acting erythropoietin-stimulating agents. Conversion to CERA from other erythropoiesis stimulating agents enabled hemoglobin levels to remain within 10 g/l (1 g/dl) of baseline values in > half the present patients, and approximately two-thirds of the patients maintained hemoglobin levels from 110 to 130 g/l. The only clinical trial that reported efficacy of CERA in kidney transplant recipients after converting from other erythropoiesis-stimulating agents confirmed the maintenance of hemoglobin levels, showing 64.3% patients with hemoglobin levels ± 10 g/l from 100 to 120 g/l; 76.2% patients with hemoglobin levels ± 10 g/l of baseline values; and 73.8% patients with hemoglobin levels from 100 to 120 g/l after switching from darbepoetin alfa every 2 weeks to once-monthly CERA. 16 Another study in CKD patients not on dialysis who changed from onceweekly darbepoetin alfa to once-monthly CERA also reported hemoglobin levels from 110 to 130 g/l in 65% to 80% patients. 39 In another observational study, CERA administration under clinical practice conditions enabled anemia to be controlled in kidney transplant recipients. 29 In patients who had not received erythropoietin-stimulating agents, starting CERA promoted increased hemoglobin levels to 110 g/l in 95% patients without the need for blood transfusions. Although further information in kidney transplant recipients is required, correction of anemia with CERA has been reported previously in CKD patients not on dialysis. In these patients, increases in hemoglobin level 10 g/l, and hemoglobin levels 110 g/l without blood transfusions, were reported in 97.5% patients who received CERA every 2 weeks. 31 In addition, increases in hemoglobin level 10 g/l, and hemoglobin level 100 g/l, were reported in 94.1% patients when CERA was administered once per month. 30 In the present study, patients who received CERA achieved hemoglobin levels > 110 g/l in 80.6% patients at 6 months and 77.15% patients at 12 months follow-up, and patients who were maintained on darbepoetin alfa achieved the same target hemoglobin levels in 59.3% patients at 6 months (P.03) and 65% patients at 12 months follow-up (not significant). The lower percentage of the present patients who had target hemoglobin levels (> 110 g/l) may be attributed to the higher frequency of iron deficiency and less frequent CERA injections in the present patients compared with patients in other studies. Previous studies showed that patients converting from other erythropoiesis-stimulating agents may achieve anemia control with lower doses of their maintenance. 29 These findings are consistent with the results of the only other clinical trial identified about the use of CERA in kidney transplant recipients, which suggested that the dose of CERA upon changing from darbepoetin alfa (< 40 μg/wk) to CERA (120 μg/mo) might be a higher dose of CERA than necessary for these patients. 38 The present results were similar, especially within 3 months after transplant. Increased hemoglobin levels were observed in patients early after transplant, with mean levels of > 110 g/l by 1 month after transplant. However, we cannot identify the specific effect of CERA on anemia correction because there was no comparison group. Further controlled studies are needed to confirm the effect of CERA in this patient population. In the present study, we converted patients from darbepoetin alfa (< 40 μg/wk, μg/wk, and > 80 μg/wk) to CERA (120 μg/mo, 200 μg/mo, and 350 μg/mo), and the follow-up dosage was adjusted according to hemoglobin levels. Administration of CERA was well tolerated by kidney transplant recipients, with an expected safety profile comparable to shorter-acting erythropoiesis-stimulating agents. This was supported by the comparable follow-up renal graft function (estimated glomerular filtration rate) (Table 3), number of antihypertensive agents, number of patients with new-onset diabetes after transplant or serious bacterial infections (Table 4), and graft and patient outcomes (Table 5 and Figures 1 and 2). This confirmed previous findings that CERA may be well tolerated in kidney transplant recipients and CKD patients. 36,40
6 Torki Al-Otaibi et al /Experimental and Clinical Transplantation (2014) 3: The present clinical trial supports the results of previous observational studies that provided valuable information about treatments administered in clinical practice. The present study was a randomized prospective clinical trial with a comparison group, and this overcame the disadvantages of a previously reported study. 41 In summary, anemia may be an important problem in kidney transplant recipients, and iron use may be suboptimal in these patients. Long-acting erythropoietin-stimulating preparations had comparable positive results. Larger and long-term studies are needed to support these observations. References 1. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16(11): Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4(12): Mitsnefes MM, Subat-Dezulovic M, Khoury PR, Goebel J, Strife CF. Increasing incidence of post-kidney transplant anemia in children. Am J Transplant. 2005;5(7): Vanrenterghem Y. Anemia after kidney transplantation. Transplantation. 2009;87(9): Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol. 2003;14(2): Ponticelli C, Villa M. Role of anaemia in cardiovascular mortality and morbidity in transplant patients. Nephrol Dial Transplant. 2002;17(suppl 1): Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002;13(4): Imoagene-Oyedeji AE, Rosas SE, Doyle AM, Goral S, Bloom RD. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol. 2006;17(11): Chhabra D, Grafals M, Skaro AI, Parker M, Gallon L. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol. 2008;3(4): Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients a prospective cohort study. Am J Transplant. 2007;7(4): Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13(2): Shah N, Al-Khoury S, Afzali B, et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation. 2006;81(8): Afzali B, Al-Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D. Anemia after renal transplantation. Am J Kidney Dis. 2006;48(4): Winkelmayer WC, Chandraker A. Posttransplantation anemia: management and rationale. Clin J Am Soc Nephrol. 2008;3(suppl 2):S49-S Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3(7): Molnar MZ, Novak M, Ambrus C, et al. Anemia in kidney transplanted patients. Clin Transplant. 2005;19(6): Winkelmayer WC, Lorenz M, Kramar R, Hörl WH, Sunder- Plassmann G. Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. Am J Transplant. 2004;4(12): Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17(3): Kamar N, Rostaing L. Negative impact of one-year anemia on longterm patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation. 2008;85(8): Molnar MZ, Czira M, Ambrus C, et al. Anemia is associated with mortality in kidney-transplanted patients - a prospective cohort study. Am J Transplant. 2007;7(4): Winkelmayer WC, Chandraker A, Alan Brookhart M, Kramar R, Sunder-Plassmann G. A prospective study of anaemia and longterm outcomes in kidney transplant recipients. Nephrol Dial Transplant. 2006;21(12): Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006;69(3): Iaina A, Silverberg DS, Wexler D. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. Nat Clin Pract Cardiovasc Med. 2005;2(2): Gleissner CA, Murat A, Schäfer S, et al. Reduced hemoglobin after heart transplantation is no independent risk factor for survival but is associated closely with impaired renal function. Transplantation. 2004;77(5): Gheith O, Wafa E, Hassan N, Mostafa A, et al. Does posttransplant anemia at 6 months affect long-term outcome of live-donor kidney transplantation? A single-center experience. Clin Exp Nephrol. 2009;13(4): KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 suppl 3):S11- S de Francisco AL, Sulowicz W, Klinger M, et al. BA16260 Study Investigators. Continuous Erythropoietin Receptor (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006;60(12): Provenzano R, Besarab A, Macdougall IC, et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol. 2007;67(5): Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008;3(2): Roger SD, Locatelli F, Woitas RP, et al. C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis. Nephrol Dial Transplant. 2011;26(12): Fliser D, Kleophas W, Dellanna F, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin. 2010;26(5): Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010;25(12):
7 226 Torki Al-Otaibi et al /Experimental and Clinical Transplantation (2014) 3: Exp Clin Transplant 33. Canaud B, Mingardi G, Braun J, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008;23(11): Levin NW, Fishbane S, Cañedo FV, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet. 2007;370(9596): Locatelli F, Villa G, de Francisco AL, et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. Curr Med Res Opin. 2007;23(5): Carreño A, Campistol JM, Arias M, Morales JM, Pallardo L, Franco A. A randomised, multicenter, phase IIIb clinical trial to evaluate efficacy and safety of C.E.R.A. once a month versus darbepoetin alfa in renal transplant recipients with chronic renal anaemia (TIVOLI Study Group) [ATC abstract 27]. Am J Transplant. 2011;11(suppl 2): Malyszko J, Glowinska I, Mysliwiec M. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease - another drawback of immunosuppression? Transplant Proc. 2012;44(10): Mann JF, de Francisco A, Nassar G, Canaud B. Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Clin Nephrol. 2011;76(1): Minutolo R, Zamboli P, Chiodini P, et al. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif. 2010;30(3): Locatelli F, Mann JF, Aldigier JC, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. Clin Nephrol. 2010;73(2): Sánchez-Fructuoso AI, Ruiz JC, Torregrosa JV, et al. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study. Adv Ther. 2012;29(11):
Prevalence of Anemia among Iraqi Patients after Renal
Original Article Prevalence of Anemia among Iraqi Patients after Renal Transplantation * Qais H. Al-Tai ** Intisar Y. Al-Ani** BSc, MSc, PhD Sc MBChB, FICMS BSc, MSc Fac Med Baghdad 2011; Vol. 53, No.
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationDose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
Adv Ther (2013) 30:1007 1017 DOI 10.1007/s25-013-0063-y ORIGINAL RESEARCH Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study Peter Choi Mourad
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationComparison of Pain and Efficacy of Darbepoetin Alfa and Epoetin Beta Pegol Treatment in Patients Receiving Peritoneal Dialysis
Original Comparison of Pain and Efficacy of Darbepoetin Alfa and Epoetin Beta Pegol Treatment in Patients Receiving Peritoneal Dialysis Tomoyuki Otsuka 1,YukinaoSakai 1,ShizukaYui 1, Masami Sukegawa 1,
More informationPost renal transplant anemia: severity, causes and their association with graft and patient survival
Schechter et al. BMC Nephrology (2019) 20:51 https://doi.org/10.1186/s12882-019-1244-y RESEARCH ARTICLE Post renal transplant anemia: severity, causes and their association with graft and patient survival
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study F. Dellanna, 1
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationAnaemia and congestive heart failure early post-renal transplantation
NDT Advance Access published November 28, 2007 Nephrol Dial Transplant (2007) 0: 1 7 doi: 10.1093/ndt/gfm815 Advance Access publication xx xx xxxx Original Article Anaemia and congestive heart failure
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationComparison of Usage and Effectiveness between Methoxy Polyethylene Glycol Epoetin Beta and Darbepoetin Alfa with Hemodialysis Patients
Journal of Pharmacy and Pharmacology 3 (2015) 182-190 doi: 10.17265/2328-2150/2015.04.004 D DAVID PUBLISHING Comparison of Usage and Effectiveness between Methoxy Polyethylene Glycol Epoetin Beta and Darbepoetin
More informationStudy of Management of anemia in Chronic Kidney Disease Patients
Review Article Study of Management of anemia in Chronic Kidney Disease Patients Meby Susan Mathew, Nama Ravi Sneha Keerthi, Neelathahalli Kasturirangan Meera* Meera N.K, Visveswarapura Institute of Pharmaceutical
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationModerators: Heather A. Nyman, Pharm.D., BCPS Clinical Pharmacist, Dialysis, University of Utah Dialysis Program, Salt Lake City, Utah
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P (Knowledge-Based Activity) Monday, October 17 1:30
More informationTHE POSSIBLE ROLE OF EARLY POST-TRANSPLANT INFLAMMATION IN LATER ANEMIA IN KIDNEY TRANSPLANT RECIPIENTS
& THE POSSIBLE ROLE OF EARLY POST-TRANSPLANT INFLAMMATION IN LATER ANEMIA IN KIDNEY TRANSPLANT RECIPIENTS Goran Imamović 1 *, Enver Zerem 2, Safet Omerović 3, Enes Osmanović 4, Emir Hodžić 1 ¹ University
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationInkidney transplant recipients, despite remarkable improvement
Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection Darshika Chhabra,* Monica Grafals,* Anton I. Skaro,* Michele Parker, and Lorenzo Gallon* *Nephrology/Transplantation,
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationImmunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P Monday, October 17 1:30 p.m. 3:30 p.m. Convention
More informationYoung Ki Lee, Sung Gyun Kim, Jang Won Seo, Ji Eun Oh, Jong-Woo Yoon, Ja-Ryong Koo, Hyung Jik Kim and Jung Woo Noh
Nephrol Dial Transplant (2008) 23: 3240 3246 doi: 10.1093/ndt/gfn255 Advance Access publication 9 May 2008 Original Article A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationLong-term prognosis of BK virus-associated nephropathy in kidney transplant recipients
Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationPatients with chronic kidney disease (CKD) are
CLINICAL INTERVENTIONS TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH KIDNEY DISEASE Jeffrey S. Berns, MD* ABSTRACT Although the specific mechanisms by which chronic kidney disease (CKD) and cardiovascular
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationPost Transplant Anaemia
11 Post Transplant Anaemia Bhadran Bose and David Mudge Princess Alexandra Hospital, Brisbane Australia 1. Introduction Anaemia, as a complication of end stage kidney disease (ESKD), is well studied (Eschbach
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationAppropriateness of anemia management in hemodialysis patients
Saudi Pharmaceutical Journal (2012) 20, 85 91 King Saud University Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com PRACTICE REPORT Appropriateness of anemia management in hemodialysis
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationRESEARCH. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study
Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study Georg Heinze, research scientist, 1 Alexander Kainz, research scientist, 2 Walter H Hörl,
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin zeta, 1000 IU/0.3ml, 2000 IU/0.6ml, 3000 IU/0.9ml, 4000 IU/0.4ml, 5000 IU/0.5ml, 6000 IU/0.6ml, 8000 IU/0.8ml, 10,000 IU/1.0ml, 20,000 IU/0.5ml, 30,000 IU/0.75ml and
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationAssociation between the malnutrition-inflammation score and post-transplant anaemia
Nephrol Dial Transplant (2011) 26: 2000 2006 doi: 10.1093/ndt/gfq690 Advance Access publication 29 November 2010 Original Articles Association between the malnutrition-inflammation score and post-transplant
More informationEfficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia
Research Article Efficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia Diana Laila Ramatillah* 1, Syed Azhar Syed Sulaiman 1, Amer Hayat Khan 1, Ong Loke Meng 2,
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Centre for Clinical Practice
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice Review consultation document Review of Clinical Guideline (CG) CG 114: Anaemia management in Chronic Kidney Disease. Background
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationIN THE LAST few decades, several important
Anemia Management for Hemodialysis Patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) Findings Francesco Locatelli, MD, Ronald
More informationUniversity of Groningen
University of Groningen Iron Deficiency, Anemia and Mortality in Renal Transplant Recipients Eisenga, Michele F.; Minovic, Isidor; Berger, Stefan P.; Ros, Jenny; van den Berg, Else; Riphagen, Ineke; Navis,
More informationMaintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
original article http://www.kidney-international.org & 2008 International Society of Nephrology Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a
More informationThe Effects of Pre- and Post-transplant Anemia on 1-Year Survival After Cardiac Transplantation
The Effects of Pre- and Post-transplant Anemia on 1-Year Survival After Cardiac Transplantation a,b Anne B. Taegtmeyer, MRCP(UK), PhD, Paula Rogers, BSc, a a b Jane B. Breen, BSc, Paul J. Barton, PhD,
More informationAnemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins
Anemia Update Peter Bárány Department of Renal Medicine/ Karolinska University Hospital and Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska Institutet,
More informationF Dellanna, R Winkler, F Bozkurt, V Schettler, S Graf, N Bockreiss, D Fliser. HAL Id: hal https://hal.archives-ouvertes.
Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study F Dellanna, R Winkler, F Bozkurt,
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationAnemia is very common among end-stage renal fail LATEST STRATEGY IN RENAL ANEMIA MANAGEMENT IN PERITONEAL DIALYSIS PATIENTS.
Proceedings of the 3rd Asian Chapter Meeting of the ISPD November 22 24, 2007, Hiroshima, Japan Peritoneal Dialysis International, Vol. 28 (2008), Supplement 3 0896-8608/08 $3.00 +.00 Copyright 2008 International
More informationInternational Journal of Current Research in Chemistry and Pharmaceutical Sciences Volume 1 Issue: Pages: 20-28
International Journal of Current Research in Chemistry and Pharmaceutical Sciences www.ijcrcps.com Volume 1 Issue: 3 2014 Pages: 20-28 (p-issn: 2348-5213; e-issn: 2348-5221) REVIEW ARTICLE PREVALENCE OF
More informationPharmacological Management of Complications of End Stage Renal Disease in Patients on Maintenance Hemodialysis.
Indian Journal of Pharmacy Practice Association of Pharmaceutical Teachers of India Pharmacological Management of Complications of End Stage Renal Disease in Patients on Maintenance Hemodialysis. 1 1 Justin
More informationTargeted Adverse Event (ADV)
North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0; 06-20-13 1.
More informationEffect of Erythropoietin on Kidney Allograft Survival Early Use After Transplantation
Transplantation Effect of Erythropoietin on Kidney Allograft Survival Early Use After Transplantation Mohsen Nafar, 1,2 Behrang Alipour Abdei, 1 Pedram Ahmadpoor, 1,2 Fatemeh Pour-Reza-Gholi, 1,2 Fariba
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationNational Institute for Health and Care Excellence
National Institute for Health and Care Excellence 2-year surveillance (2017) Chronic kidney disease: managing anaemia (2015) NICE guideline NG8 Appendix A3: Summary of new evidence from surveillance Diagnostic
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationRecurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
More informationDiabetes in Renal Patients. Contents. Understanding Diabetic Nephropathy
Diabetes in Renal Patients Contents Understanding Diabetic Nephropathy What effect does CKD have on a patient s diabetic control? Diabetic Drugs in CKD and Dialysis Patients Hyper and Hypoglycaemia in
More informationImpact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival
Nephrol Dial Transplant (2005) 20 [Suppl 8]: viii8 viii12 doi:10.1093/ndt/gfh1110 Impact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival Mariarosaria Campise
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationChapter 3: Use of ESAs and other agents* to treat anemia in CKD Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 3 & 2012 DIGO Chapter 3: Use of ESAs and other agents* to treat anemia in CD idney International Supplements (2012) 2, 299 310; doi:10.1038/kisup.2012.35 ESA
More informationAnemia response to Methoxy
Open Access Journal of Clinical Nephrology Research Article Anemia response to Methoxy ISSN 2576-9529 Polyethylene Glycol-Epoetin Beta (Mircera) versus Epoetin Alfa (Eprex) in patients with chronic Kidney
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationProteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
Trends Fritz in Transplant. Diekmann: 2011;5:139-43 Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationContinuous Erythropoietin Receptor Activator (Mircera ) for Renal Anemia
Issues in Emerging Health Technologies Continuous Erythropoietin Receptor Activator (Mircera ) for Renal Anemia Issue 113 February 2008 Summary Continuous erythropoietin receptor activator (CERA) is a
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationImpact of correction of anemia on major complication of chronic renal diseases
Original article: Impact of correction of anemia on major complication of chronic renal diseases Md Hamid Ali, Atanu Roy Chaudhry, Kapildev Mondal, Arijit Sinha Department of General Medicine, Murshidabad
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPrevalence and management of post-transplant anemia in long-term follow-up of Chinese kidney transplant recipients: a single-center report
Wu et al. European Journal of Medical Research 2013, 18:45 EUROPEAN JOURNAL OF MEDICAL RESEARCH RESEARCH Open Access Prevalence and management of post-transplant anemia in long-term follow-up of Chinese
More informationEPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
PATIENT BLOOD MANAGEMENT DALLA TEORIA ALLA PRATICA 16 FEBBRAIO 2018 EPO e Ferro in Emodialisi: Il PBM al suo esordio Lucia Del Vecchio Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
More informationABSTRACT ORIGINAL RESEARCH
Adv Ther (2014) 31:1155 1168 DOI 10.1007/s12325-014-0161-5 ORIGINAL RESEARCH Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationC.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study
Hemodialysis International 2009; ]]:1 7 once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study Michèle KESSLER, 1 Alberto MARTÍNEZ-CASTELAO, 2 Kostas C.
More informationCase Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration Rate
Case Reports in Transplantation, Article ID 190516, 4 pages http://dx.doi.org/10.1155/2014/190516 Case Report Beneficial Effect of Conversion to Belatacept in Kidney-Transplant Patients with a Low Glomerular-Filtration
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationProgress in Pediatric Kidney Transplantation
Send Orders for Reprints to reprints@benthamscience.net The Open Urology & Nephrology Journal, 214, 7, (Suppl 2: M2) 115-122 115 Progress in Pediatric Kidney Transplantation Jodi M. Smith *,1 and Vikas
More informationANEMIA IS A COMMON COMPLICATION of endstage
Impact on Health-Related Quality of Life in Kidney Transplant Recipients with Late Posttransplant Anemia Administered Darbepoetin Alfa: Results from the STRATA Study R.D. Bloom, P. Bolin, S.R. Gandra,
More informationComparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital
Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationTID-17-C-005.R1, Received: 21 January 2017, Revised: 13 June 2017, Accepted: 29 June 2017
DR ROMÁN HERNÁNDEZ-GALLEGO (Orcid ID : 0000-0002-5670-941X) Article type : Case Report TID-17-C-005.R1, Received: 21 January 2017, Revised: 13 June 2017, Accepted: 29 June 2017 CASE REPORT Anemia as very
More information